Last reviewed · How we verify
Hydroxycarbamide film-coated tablet
Hydroxycarbamide film-coated tablet is a Small molecule drug developed by Theravia. It is currently in Phase 1 development.
At a glance
| Generic name | Hydroxycarbamide film-coated tablet |
|---|---|
| Sponsor | Theravia |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease (PHASE2)
- SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial) (PHASE2)
- A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Siklos® in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydroxycarbamide film-coated tablet CI brief — competitive landscape report
- Hydroxycarbamide film-coated tablet updates RSS · CI watch RSS
- Theravia portfolio CI
Frequently asked questions about Hydroxycarbamide film-coated tablet
What is Hydroxycarbamide film-coated tablet?
Hydroxycarbamide film-coated tablet is a Small molecule drug developed by Theravia.
Who makes Hydroxycarbamide film-coated tablet?
Hydroxycarbamide film-coated tablet is developed by Theravia (see full Theravia pipeline at /company/theravia).
What development phase is Hydroxycarbamide film-coated tablet in?
Hydroxycarbamide film-coated tablet is in Phase 1.
Related
- Manufacturer: Theravia — full pipeline